BackMeribank Biotech , Ltd Overview
Meribank Biotech Co., Ltd

Meribank Biotech , Ltd Return on Equity

Meribank Biotech , Ltd (4724.TWO) has a ROE of -17.14%, below the Healthcare sector average of 13.1%.

Get informed when a big investor buys or sells

+ Follow

ROE

-17.14%

Return on Equity

-17.14%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

Meribank Biotech , Ltd (4724.TWO) FAQ

Meribank Biotech , Ltd's return on equity stands at -17.14%. That is below the Healthcare sector average of 13.1%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Meribank Biotech , Ltd sits lower the Healthcare benchmark (13.1%) with a ROE of -17.14%. That is roughly 230.8% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

A ROE of -17.14% for Meribank Biotech , Ltd means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.

The history chart shows how Meribank Biotech , Ltd's ROE evolved across reporting periods, while the comparison chart places 4724.TWO next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, ROE is commonly used to spot outliers. Meribank Biotech , Ltd's reading of -17.14% (sector avg 13.1%) is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.